

DOCON TECHNOLOGIES PRIVATE LIMITED

August 13, 2026

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400 073	

Sub: Release of Pledge on 1,75,00,000 equity Shares of Thyrocare Technologies Limited
Ref: Disclosures pursuant to Regulations 29(2), 31(2) and Regulation 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir & Madam,

We refer to our earlier disclosures dated September 24, 2025, November 11, 2025, December 05, 2025, March 31, 2026 and April 20, 2026 made under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("**SEBI SAST Regulations**"), in respect of the encumbrance created by Docon Technologies Private Limited ("**Docon**"), Promoter of Thyrocare Technologies Limited ("**the Company**" / "**Thyrocare**"), in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee in connection with the secured, unlisted, Non-Convertible Debentures ("**NCDs**") issued by API Holdings Limited, the holding company of Docon.

Docon is a wholly-owned subsidiary of API Holdings Limited and is the promoter of the Company. Docon holds 9,69,69,696 equity shares, representing 60.92% of the equity share capital of the Company. The aforesaid shares were pledged in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee, as security for the NCDs issued by API Holdings Limited. As on the date of this disclosure, the outstanding principal amount of the aforesaid NCDs is INR 10,500 million. The shareholding and encumbered shareholding percentages stated in this disclosures are based on the shareholding as on August 11, 2026, being the date of release of pledge.

We wish to inform you that the pledge on 1,75,00,000 equity shares of the Company has now been released by Catalyst Trusteeship Limited, acting as the Debenture Trustee on August 11, 2026.


Accordingly, pursuant to Regulations 29(2), 31(2) and 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find enclosed the requisite disclosures in respect of **the release of pledge on 1,75,00,000 equity shares of the Company**, held by Docon, which were pledged in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee.

The requisite disclosures are enclosed as under:

1. Disclosure under Regulation 29(2) of the SEBI (SAST) Regulations: **Annexure I**
2. Disclosure under Regulation 31(2) & (3) of the SEBI (SAST) Regulations: **Annexure II**

You are requested to take the same on record

For Docon Technologies Private Limited


Madhuri Sudhir Sarangdhar
Company Secretary



DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure I

Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Thyrocare Technologies Limited ('Thyrocare')		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: "Docon Technologies Private Limited PAC: API Holdings Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share /voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a. ### Shares carrying voting rights	NIL	NIL	NIL
b. ### Shares in the nature of encumbrance (pledge /lien/ non-disposal undertaking/ others)	9,69,69,696	60.92	60.75
c. Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
e. Total (a+b+c+d)	9,69,69,696	60.92	60.75
Details of acquisition/sale			
a. Shares carrying voting rights acquired/sold	Nil	Nil	Nil
b. VRs acquired /sold otherwise than by shares	Nil	Nil	Nil
c. Warrants/convertible securities/any other	Nil	Nil	Nil
d. instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold Shares encumbered /- invoked/released by the acquirer)	1,75,00,000	10.99	10.96
e. Total (a+b+c+/-d)	1,75,00,000	10.99	10.96

DOCON TECHNOLOGIES PRIVATE LIMITED

After the acquisition/sale, holding of:			
a. Shares carrying voting rights	1,75,00,000	10.99	10.96
b. ## Shares encumbered with the acquirer	7,94,69,696	49.93	49.79
c. VRs otherwise than by shares	Nil	Nil	Nil
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
e. Total (a+b+c+d)	9,69,69,696	60.92	60.75
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Release of pledge over 1,75,00,000 equity shares of Thyrocare Technologies Limited held by Docon Technologies Private Limited (Promoter of Thyrocare Technologies Limited), which had been pledged in favour of Catalyst Trusteeship Limited in connection with the existing Non-Convertible Debentures ("NCDs") issued by API Holdings Limited.		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	August 11, 2026 (Release of Pledge)		
Equity share capital / total voting capital of the TC before the said acquisition / sale	15,91,65,315 Equity shares having face value of Rs. 10 each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	15,91,65,315 Equity shares having face value of Rs. 10 each		
Total diluted share/voting capital of the TC after the said acquisition	15,96,30,252 equity shares having face value of Rs. 10 each		


(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

#Docon has not acquired any additional equity shares pursuant to the release of pledge. The release merely resulted in reduction of the number of encumbered shares from 9,69,69,696 to 7,94,69,696, while Docon's total shareholding remained unchanged at 9,69,69,696 equity shares as on August 11, 2026.

The shares pledged in favour of Catalyst Trusteeship Limited are disclosed under the "shares in the nature of encumbrance" category. Since the same shares are also carrying voting rights of Docon, the shares are not separately included under "shares carrying voting rights" to avoid duplication. Docon continues to have voting rights in respect of the entire 9,69,69,696 equity shares.

For and on behalf of **Docon Technologies Private Limited**


Madhuri Sudhir Sarangdhar
 Company Secretary



Date: August 13, 2026